Literature DB >> 7975205

Requirement of casein kinase II-mediated phosphorylation for the transcriptional activity of human respiratory syncytial viral phosphoprotein P: transdominant negative phenotype of phosphorylation-defective P mutants.

B Mazumder1, S Barik.   

Abstract

The transcription complex of the human respiratory syncytial virus was biochemically dissected and reconstituted in vitro with purified viral macromolecules. The minimal complex consisted of the viral N-RNA template, viral phosphoprotein (P), and the large protein (L) along with host cellular factor(s), possibly actin. Active transcription could also be reconstituted using bacterially synthesized recombinant P protein provided the P protein was phosphorylated by cellular casein kinase II. Elimination of phosphorylation by inhibition of CKII or by mutation of the Ser residue at position 237 of the P protein also abrogated RSV transcription. In addition, the phosphorylation-defective P mutants exhibited a trans-dominant negative phenotype, consistent with the finding that the mutant proteins bound to the N-RNA template as efficiently as the wild type. Once engaged in transcription, however, the wild-type P protein became refractory to trans-inhibition by the mutant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975205     DOI: 10.1006/viro.1994.1624

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Phosphorylation within the amino-terminal acidic domain I of the phosphoprotein of vesicular stomatitis virus is required for transcription but not for replication.

Authors:  A K Pattnaik; L Hwang; T Li; N Englund; M Mathur; T Das; A K Banerjee
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Respiratory syncytial virus M2-1 protein requires phosphorylation for efficient function and binds viral RNA during infection.

Authors:  T L Cartee; G W Wertz
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Profilin is required for optimal actin-dependent transcription of respiratory syncytial virus genome RNA.

Authors:  E Burke; N M Mahoney; S C Almo; S Barik
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  Initiation and regulation of paramyxovirus transcription and replication.

Authors:  Sarah L Noton; Rachel Fearns
Journal:  Virology       Date:  2015-02-13       Impact factor: 3.616

5.  Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions.

Authors:  B García-Barreno; T Delgado; J A Melero
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  Optimal replication activity of vesicular stomatitis virus RNA polymerase requires phosphorylation of a residue(s) at carboxy-terminal domain II of its accessory subunit, phosphoprotein P.

Authors:  L N Hwang; N Englund; T Das; A K Banerjee; A K Pattnaik
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  The respiratory syncytial virus polymerase can perform RNA synthesis with modified primers and nucleotide analogs.

Authors:  Barbara Ludeke; Rachel Fearns
Journal:  Virology       Date:  2019-11-06       Impact factor: 3.616

8.  Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor.

Authors:  Stephen W Mason; Carol Lawetz; Yvon Gaudette; Florence Dô; Erika Scouten; Lisette Lagacé; Bruno Simoneau; Michel Liuzzi
Journal:  Nucleic Acids Res       Date:  2004-09-08       Impact factor: 16.971

9.  Functional correlations of respiratory syncytial virus proteins to intrinsic disorder.

Authors:  Jillian N Whelan; Krishna D Reddy; Vladimir N Uversky; Michael N Teng
Journal:  Mol Biosyst       Date:  2016-04-26

10.  Cellular protein kinase C isoform zeta regulates human parainfluenza virus type 3 replication.

Authors:  B P De; S Gupta; S Gupta; A K Banerjee
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.